ClinicalTrials.gg
Enrolling by invitationNCT07214896HEALTHUpdated Nov 5, 2026

Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings

A Phase 2 interventional study of Skin Cell Dip and Stem Cell Dip in Mobility Impairment, Clinical Workflow Optimization and Sanitation Protocol Compliance, sponsored by Truway Health, Inc.. Enrolling by invitation at 4 sites in 3 countries. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Truway Health, Inc. · Phase 2, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Sex
All
01

Study summary

This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Humanoid units are enhanced via biotech integration and compensated through blockchain-based wage tokens. Outcomes will inform coalition governance, wage calibration, and metro-scale deployment strategies.

Read the detailed description

The HEALTH trial (Humanoid Evaluation and Learning Trial in Healthcare) is a coalition-aligned clinical study designed to assess the deployment of humanoid robotics in real-world care environments. Conducted across metro facilities in New York, Austin, Frankfurt, and Tokyo, the trial evaluates robotic performance in patient intake, sanitation, mobility assistance, and ESG-linked operations.

Humanoid units are enhanced through biotech integration, including skin cell regeneration dips and stem cell neural augmentation. Each unit is tracked via biometric audit scoring across five dimensions: motor function, cognitive response, ESG compliance, biotech retention, and human interaction. Scores are notarized via SHA-256 and published to the coalition dashboard.

Wage tokens (HumanoidWage, HMW) are minted based on performance thresholds and distributed through smart contracts to deployed units. FX arbitrage across Tokyo and Frankfurt informs reinvestment logic and 1031 exchange-backed yield farming pools. DAO voting governs deployment, wage calibration, and protocol expansion.

This trial aims to establish scalable, transparent frameworks for humanoid integration in healthcare, anchored in coalition governance, public oversight, and metro-ready infrastructure.

02

Conditions studied

  • Mobility Impairment
  • Clinical Workflow Optimization
  • Sanitation Protocol Compliance
  • ESG-linked Healthcare Robotics Deployment

Keywords

  • Humanoid robotics in healthcare
  • Clinical deployment of humanoid robots
  • Biometric audit scoring
  • ESG compliance in clinical settings
  • Stem cell integration in robotics
  • Skin cell regeneration for humanoid units
  • Blockchain wage token for robotics
  • FX arbitrage in healthcare robotics
  • Coalition-aligned clinical trial
  • Metro-scale robotics deployment
  • Patient mobility assistance
  • Sanitation protocol automation
  • DAO-governed healthcare infrastructure
  • 1031 exchange yield farming in clinical care
  • Adaptive learning in humanoid systems
  • Public oversight of robotic healthcare trials
03

In context

Lead sponsor

Truway Health, Inc. is the lead sponsor of 16 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Age 18-75 years

Able to provide

Facility staff, clinical auditors, ESG observers, or coalition stakeholders

Willing to interact with humanoid robotics in clinical workflows

Available for biometric feedback and observational logging over 90 days

Exclusion criteria

Exclusion Criteria:

- Cognitive impairment preventing

Active infectious disease requiring isolation

Prior adverse reaction to biotech-enhanced robotics

Involvement in conflicting clinical trials

Inability to comply with protocol procedures or coalition transparency requirements

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    New York Facility - Skin Cell Deployment

    Humanoid units deployed in patient intake and sanitation roles. Enhanced with keratinocyte-based skin cell dips to improve tactile sensitivity and surface regeneration. Assigned Roles: Intake assistant, sanitation technician Biometric Focus: Motor function, ESG compliance

    Biological: Skin Cell Dip

  • Experimental
    Austin Facility - Stem Cell Cognitive Enhancement

    Humanoid units deployed in mobility and R\&D support roles. Enhanced with iPSC-derived stem cell dips targeting neural responsiveness and adaptive learning. Assigned Roles: Mobility assistant, lab technician Biometric Focus: Cognitive response, biotech retention

    Biological: Stem Cell Dip

  • Experimental
    Frankfurt Facility - ESG Optimization

    Humanoid units deployed in ESG-linked sanitation and logistics roles. Monitored for energy usage, carbon offset, and protocol adherence. Assigned Roles: ESG sanitation, logistics handler Biometric Focus: ESG compliance, human interaction

    Behavioral: ESG Compliance Monitoring, Operational protocol

  • Experimental
    Tokyo Facility - Wage Token Calibration

    Humanoid units deployed in public interface and intake roles. Wage tokens minted based on biometric audit scores and task completion. Assigned Roles: Receptionist, intake coordinator Biometric Focus: Wage token distribution, interaction scoring

    Other: Wage Token Distribution

Interventions

  • BiologicalSkin Cell Dip

    Lab-grown keratinocyte dip applied to humanoid units to improve tactile sensitivity and surface regeneration.

  • BiologicalStem Cell Dip

    iPSC-derived neuroblast dip applied to humanoid units to enhance neural responsiveness and adaptive learning.

  • OtherWage Token Distribution

    HumanoidWage (HMW) tokens minted and distributed based on biometric audit scores and ESG task completion.

    Also known as: Blockchain-based compensation

  • BehavioralESG Compliance Monitoring, Operational protocol

    Real-time tracking of energy usage, sanitation cycles, and carbon offset metrics via coalition dashboard.

06

What researchers measure

Primary outcomes

  1. Biometric Audit Score ≥85 Across Five Performance Dimensions

    This outcome assesses the performance of humanoid robotics units deployed in coalition-aligned healthcare settings. Each unit is scored across five biometric dimensions: motor function, cognitive response, ESG compliance, biotech integration, and human interaction. Scores are notarized via SHA-256 and published to the coalition dashboard. Units achieving a composite score ≥85 are eligible for wage token bonuses, dip protocol expansion, and DAO-backed facility scaling.

    Time frame: Measured at Day 30 Post-Deployment

Secondary outcomes

  1. ESG Audit Compliance Score ≥90

    Measured at Day 60 Post-Deployment

    Time frame: Humanoid units are evaluated for ESG-linked performance including energy usage, sanitation protocol adherence, and carbon offset metrics. Scores are published to the coalition dashboard and notarized via SHA-256. Units scoring ≥90 contribute to DAO-backe

  2. Wage Token Distribution Volume per Unit

    Tracks the volume of HumanoidWage (HMW) tokens minted and distributed to each humanoid unit based on biometric audit scores and task completion. Token flow is logged on-chain and used to calibrate coalition wage pools and reinvestment logic.

    Time frame: Continuous Monitoring Over 90 Days

  3. Clinical Workflow Efficiency Increase ≥15%

    Assesses improvements in patient intake speed, sanitation cycle time, and mobility assistance throughput across facilities. Benchmarked against pre-deployment baselines and validated by coalition auditors.

    Time frame: Measured at Day 90 Post-Deployment

07

Study locations

4 sites
  • Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016
    New York, New York 10016, United States
  • Coalition Retrofit Clinic - Austin, TX
    Austin, Texas 73301, United States
  • ESG Compliance Lab
    Frankfurt, 60435, Germany
  • Public Interface Pilot
    Tokyo, 100-1000, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) collected during this trial-including biometric audit scores, ESG compliance metrics, and wage token distribution logs-will be shared with qualified researchers upon request. Data will be de-identified, SHA-256 notarized, and made available through Truway Health's coalition dashboard and secure data access portal. Access will require submission of a research proposal, DAO approval, and compliance with coalition transparency protocols.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD and supporting documents will be available starting April 1, 2026, following primary study completion. Access will remain open for 5 years, until April 1, 2031, via Truway Health's secure coalition dashboard and data access portal.

Access criteria: Qualified researchers, coalition partners, and regulatory agencies may request access to de-identified IPD, biometric scores, ESG metrics, wage token logs, and analytic code. Access requires submission of a research proposal, DAO approval, and compliance with Truway Health's transparency and data governance protocols.

Data sharing details ↗ · www.truwayhealth.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Oct 2031, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2025
First posted
Oct 9, 2025
StartActual
Oct 6, 2025
Primary completionEst.
Oct 6, 2031
CompletionEst.
Oct 6, 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07214896
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Oct 6, 2025
Primary completion
Oct 6, 2031 (estimated)
Completion
Oct 6, 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Gavin C Solomon, President & CEO
principal investigator · Truway Health, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion